Email this article USE OF INJECTABLE VALPROATE FORMULATIONS IN STATUS EPILEPTICUS IN ADULTS AND CHILDREN
- Authors: Kholin A.A.1,2
-
Affiliations:
- Department of Neurology, Neurosurgery, and Medical Genetics, Faculty of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
- Psychoneurology Unit Two, Russian Children’s Clinical Hospital, Ministry of Health of Russia, Moscow
- Issue: Vol 9, No 3 (2014)
- Pages: 23-29
- Section: AUTHENTIC ARTICLES
- Published: 18.04.2015
- URL: https://rjdn.abvpress.ru/jour/article/view/27
- DOI: https://doi.org/10.17650/2073-8803-2014-9-3-23-29
- ID: 27
Cite item
Full Text
Abstract
One of the most actual problems in emergency neurology is therapy of status epilepticus (SE). Antiepileptic drugs used in therapy of SE must be: 1) simple in usage; 2) have rapid action; 3) have prolonged antiepileptic action; 4) demonstrate minimal side effects on cardiorespiratory system and other vital functions. Unfortunately, such drugs traditional used in therapy of SE as benzodiazepines, phenytoin and barbiturates don’t fulfill all this four qualities. Numerous clinical investigations of last 15 years demonstrated that such drugs are intravenous valproates. Intravenous form of valproate (Convulex) is rational alternative for benzodiazepines in convulsive SE and drug of choice in treatment of symptomatic status in acute brain disturbances and in patients in coma, at non-convulsive forms of SE and in cases of high risk of depression of cardiorespiratory activity. Treatment of SE could be started from high intravenous rapid dose 15 mg / kg given in 5 minutes. 30 minutes later intravenous infusion therapy 1 mg / kg / hour with Convulex should be done. Moderate doses of intravenous Convulex for adults are 20 mg / kg, for adolescents – 25 mg / kg, and for children – 30 mg / kg.
About the authors
A. A. Kholin
Department of Neurology, Neurosurgery, and Medical Genetics, Faculty of Pediatrics,N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow;
Psychoneurology Unit Two, Russian Children’s Clinical Hospital, Ministry of Health of Russia, Moscow
Author for correspondence.
Email: drkholin@mail.ru
Russian Federation
References
Supplementary files
